Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Exhilarating discussions on the latest and greatest in precision oncology-where the field is headed, how Nature medicine is championing cutting‑edge science, and what the future holds.
Always a delight to get brilliant insights from Saheli Sadanand, Deputy Editor at Nature Medicine.”
Other articles featuring Vivek Subbiah on OncoDaily.